GCSEs in smaller-entry subjects – and most A-level exams – could be moved onto screens by the end of the decade ...

Exams regulator Ofqual is consulting on allowing exam boards to each submit proposals for two qualifications with onscreen ...

HSDC is excited to announce that the college will soon be offering a T Level in Science, as well as a Science GCSE Suite, ...

Few neighborhoods in Cambridge have seen their fortunes change as dramatically as Kendall Square. Kendall was once known for churning out soap and vulcanized rubber, then manufacturing electronics as ...

After years on the sidelines while investors piled into the next big thing in AI or crypto, biotech is back in focus. The question is whether this rally marks a real recovery or just another ...

Something unusual is happening to biotech stocks: They’re going up. A drug-pricing deal between Pfizer and the White House and a spate of deals have sent the SPDR S&P Biotech exchange-traded fund up 9 ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

George is a professor of genetics at Harvard Medical School and professor of health sciences and technology at Harvard and MIT. He is a prolific researcher studying genetic sequencing, genome editing, ...

Mr. Dreyer is an American editor and writer who lives in Shanghai. Just outside Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and ...

As biotech companies struggle, laying off staff and cutting drug research, a well-funded firm in Southern California watches closely for the right time to strike. This year, it’s struck again and ...